(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The Kansas City Chiefs should add to their defensive end room by selecting Miami Hurricanes pass rusher Rueben Bain Jr. in ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bain is closing its business in Johannesburg, likely bringing to an end a yearslong battle to try and restore its reputation.

The Cleveland Browns have had their problems recently, but one area of the roster that's stood out is the defensive line.

Bain & Co exits South Africa after Zondo fallout; Athol Trollip lays charges against Paul O’Sullivan amid a feud over ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...